Ossianix is responding to the COVID-19 pandemic by developing therapeutic single domain VNAR antibodies to the COVID-19 spike protein.

By

Ossianix is responding to the COVID-19 pandemic by developing therapeutic single domain VNAR antibodies to the COVID-19 spike protein.

See more here

Comments are closed.